Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,257 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Local Disease Clear all
Terminated Phase 2 Interventional Results available

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

NCT02560051
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Doxorubicin, Ketoconazole, Docetaxel, Estramustine, Degarelix
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 1Phase 2 Interventional

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

NCT06661902
View directory record Official record
Conditions
Prostate Cancer
Interventions
Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

NCT05325853
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Proparacaine Ophthalmic
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
Up to 10 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Nov 9, 2026, 2:56 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain

NCT04060875
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Fibromyalgia, Upper Extremity Dysfunction, Complex Regional Pain Syndromes, Phantom Limb Pain, Rheumatoid Arthritis, Carpal Tunnel Syndrome, Repetitive Strain Injury
Interventions
Karuna Labs Virtual Reality Software
Device
Lead sponsor
Karuna Labs Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Nov 9, 2026, 2:56 PM EST
Active, not recruiting Phase 3 Interventional

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

NCT03778957
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE)
Drug · Other · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Costa Mesa, California • La Jolla, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Active, not recruiting Not applicable Interventional

Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S

NCT01984710
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Medtronic Activa PC+S System
Device
Lead sponsor
Emory University
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 2 Interventional Results available

Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee

NCT02637323
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006 32 mg, TCA IR 40
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Canoga Park, California • San Diego, California • Hialeah, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Nov 9, 2026, 2:56 PM EST
Completed No phase listed Observational

Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study

NCT03054961
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Near-infrared spectroscopy
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
7 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 9, 2026, 2:56 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy

NCT04019834
View directory record Official record
Conditions
Breast Cancer, Mastectomy, Anesthesia, Local, Narcotic Use
Interventions
regional nerve block with local anesthesia of bupivacaine with steroid, Placebo regional nerveblock with normal saline
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 9, 2026, 2:56 PM EST
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Investigation of the Interplay Between Local Oral Inflammation, Microbiota and Systemic Immune Responses.

NCT06966492
View directory record Official record
Conditions
Gingival Inflammation
Interventions
Stannous Fluoride Toothpaste (SnF)
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 2 Interventional

Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00016367
View directory record Official record
Conditions
Lung Cancer
Interventions
Trastuzumab, Cisplatin, Gemcitabine Hydrochloride
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 3 Interventional Results available

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

NCT03237481
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

NCT00479765
View directory record Official record
Conditions
Glioblastoma Multiforme, Brain Neoplasms
Interventions
OncoGel (ReGel/Paclitaxel)
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Nov 9, 2026, 2:56 PM EST
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Regional Lipolysis Insulin Regulation

NCT06392854
View directory record Official record
Conditions
Obesity
Interventions
Insulin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine

NCT02620683
View directory record Official record
Conditions
Blood Levels of Buffered vs Non-buffered Lidocaine, Anesthetics, Local
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 9, 2026, 2:56 PM EST
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Two Point Discrimination

NCT03686748
View directory record Official record
Conditions
Ehlers-Danlos Syndrome (EDS), Complex Regional Pain Syndrome (CRPS), Amplified Musculoskeletal Pain Syndrome (AMPS), Low Back Pain, Fibromyalgia, Chronic Widespread Pain
Interventions
Two-point discrimination training, One-point discrimination training
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 4 Interventional

Liposomal Bupivacaine Versus Bupivacaine for for Postoperative Pain Control in Shoulder Surgery

NCT04180943
View directory record Official record
Conditions
Anesthesia, Local
Interventions
interscalene nerve block
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Nov 9, 2026, 2:56 PM EST
Active, not recruiting Phase 3 Interventional

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

NCT03927027
View directory record Official record
Conditions
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
Isosulfan Blue, Axillary Lymph Node Dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
96
States / cities
Little Rock, Arkansas • La Jolla, California • Martinez, California + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bupivacaine for Post-operative Pain in Mohs

NCT04362566
View directory record Official record
Conditions
Pain, Postoperative, Narcotic Use
Interventions
Bupivacaine, Placebo Saline
Drug · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 2 Interventional Results available

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

NCT00024258
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
arsenic trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Nov 9, 2026, 2:56 PM EST
Completed Phase 4 Interventional

Continuous Local Infusion of Anesthetic at the Incisional Site for Scoliosis Surgery

NCT00508066
View directory record Official record
Conditions
Scoliosis
Interventions
Bupivacaine, Normal Saline
Drug
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
8 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Nov 9, 2026, 2:56 PM EST